Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

van Oosterwijk, JG; Meijer, D; van Ruler, MA; van den Akker, BE; Oosting, J; Krenács, T; Picci, P; Flanagan, AM; Liegl-Atzwanger, B; Leithner, A; Athanasou, N; Daugaard, S; Hogendoorn, PC; Bovée, JV.
Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.
Am J Pathol. 2013; 182(4):1347-1356 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Leithner Andreas
Liegl-Atzwanger Bernadette
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
The mesenchymal, clear cell, and dedifferentiated chondrosarcoma subtypes are extremely rare, together constituting 10% to 15% of all chondrosarcomas. Their poor prognosis and lack of efficacious treatment emphasizes the need to elucidate the pathways playing a pivotal role in these tumors. We constructed tissue microarrays containing 42 dedifferentiated, 23 clear cell, and 23 mesenchymal chondrosarcomas and performed immunohistochemistry to study the expression of growth plate-signaling molecules and molecules shown to be involved in conventional chondrosarcoma. We observed high expression of SOX-9 and FGFR-3, as well as aberrant cellular localization of heparan sulfate proteoglycans, in all subtypes. TGFβ signaling through p-SMAD2 and PAI-1 was highly active in all chondrosarcoma subtypes, which suggests that TGFβ inhibitors as a possible therapeutic strategy in rare chondrosarcoma subtypes. As in conventional chondrosarcoma, antiapoptotic proteins (Bcl-2, and/or Bcl-xl) were highly expressed in all subtypes. Inhibition with the BH-3 mimetic ABT-737 rendered dedifferentiated chondrosarcoma cell lines sensitive to doxorubicin or cisplatin. Our data indicate that antiapoptotic proteins may play an important role in chemoresistance, suggesting a promising role for targeting Bcl-2 family members in chondrosarcoma treatment, irrespective of the subtype.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Antineoplastic Agents - pharmacology
Cell Dedifferentiation - drug effects
Chondrosarcoma, Mesenchymal - classification
Drug Resistance, Neoplasm - drug effects
Female -
Humans -
Immunohistochemistry -
Male -
Middle Aged -
Molecular Targeted Therapy -
Neoplasm Proteins - metabolism
Paraffin Embedding -
Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors
Sarcoma, Clear Cell - classification
Signal Transduction - drug effects
Tissue Fixation -
Transforming Growth Factor beta - antagonists & inhibitors
Young Adult -

© Meduni Graz Impressum